Correction: Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis
Frontiers in Pharmacology · 08.01.2026 · 16
DOI: 10.3389/fphar.2025.1678247 ↗Kurz gefasst
Korrektur in der Zeitschrift Frontiers in Pharmacology, online erschienen am 08.01.2026. Verfasst von Zhengxiao Ouyang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Powder Metallurgy, Central South University, Changsha, China. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
[This corrects the article DOI: 10.3389/fphar.2019.00584.].
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Powder Metallurgy, Central South University, Changsha, China.
- Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.
Zitieren
APA
Ouyang, Z., Huang, Q., Liu, B., Wu, H., Liu, T., & Liu, Y. (2026). Correction: Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1678247
Vancouver
Ouyang Z, Huang Q, Liu B, Wu H, Liu T, Liu Y. Correction: Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis. Frontiers in Pharmacology. 2026;16. doi:10.3389/fphar.2025.1678247
BibTeX
@article{Ouyang2026,
author = {Ouyang, Zhengxiao and Huang, Qianli and Liu, Bin and Wu, Hong and Liu, Tang and Liu, Yong},
title = {Correction: Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {16},
doi = {10.3389/fphar.2025.1678247}
}
EUVIMED